| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
S186 targets strontium ions (Sr²⁺). As a strontium-specific chelating agent, it binds to strontium ions with high affinity and selectivity, forming stable complexes that facilitate the removal of strontium from the body. This property makes it useful for the treatment of strontium poisoning or contamination.
|
|---|---|
| ln Vitro |
In vitro, S186 acts as a strontium-specific chelating agent. Its activity is assessed by measuring its ability to bind to strontium ions in solution and form stable complexes. The compound's selectivity for strontium over other divalent cations (e.g., calcium) is also evaluated.
|
| ln Vivo |
In vivo, S186 has been approved by the Shanghai Municipal Health Bureau for emergency medical use in China for the treatment of strontium poisoning or contamination. Its strontium-specific chelation properties allow it to effectively remove strontium from the body, reducing its toxic effects.
|
| Enzyme Assay |
In vitro chelation assays for S186 are performed by incubating the compound with strontium ions in solution and measuring the formation of stable complexes using spectroscopic or potentiometric methods. The compound's binding affinity and selectivity for strontium over other cations are determined from these assays.
|
| Cell Assay |
In vitro cellular assays for S186 are not typically performed, as its mechanism of action is based on chelation of strontium ions rather than modulation of cellular processes. Its effects on cells would be related to the removal of strontium from the extracellular environment.
|
| Animal Protocol |
In vivo animal experiments for S186 would typically involve administration to animals exposed to strontium, followed by measurement of strontium levels in blood, urine, and tissues to assess the compound's efficacy in removing strontium from the body. These studies would support its use as a medical countermeasure for strontium poisoning.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of S186 have been characterized to support its use as a medical countermeasure. The compound has a molecular weight of 321.15, molecular formula C5H10CaNNaO7P2, and a purity of >98%. It is a sodium salt of calcium-acetylpropylamine phosphonate (APA). Further PK details are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
The toxicity profile of S186 has been evaluated to support its approval for emergency medical use. As a chelating agent, its safety profile is characterized by its effects on electrolyte balance and potential for chelation of essential divalent cations. Specific toxicity data, including organ-specific effects and dose-limiting toxicities, are available from regulatory submissions.
|
| References | |
| Additional Infomation |
S186 is a new strontium-specific chelating agent that has been approved by the Shanghai Municipal Health Bureau for emergency medical use in China. It is a sodium salt of calcium-acetylpropylamine phosphonate (APA) and is used for the treatment of strontium poisoning or contamination. This product is for research use only.
|
| Molecular Formula |
C5H13NO7P2.CA+2.NA+
|
|---|---|
| Molecular Weight |
324.175
|
| Exact Mass |
323.969
|
| CAS # |
97759-16-5
|
| PubChem CID |
127255645
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
319
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(NC(=O)C)(P(=O)(O)O)P(=O)(O)O.[Na].[Ca]
|
| InChi Key |
WPTHTLCSASTWJP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H13NO7P2.Ca.Na/c1-3-5(6-4(2)7,14(8,9)10)15(11,12)13;;/h3H2,1-2H3,(H,6,7)(H2,8,9,10)(H2,11,12,13);;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~77.85 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0847 mL | 15.4235 mL | 30.8471 mL | |
| 5 mM | 0.6169 mL | 3.0847 mL | 6.1694 mL | |
| 10 mM | 0.3085 mL | 1.5424 mL | 3.0847 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
